Picture of Oncolytics Biotech logo

ONCY — Oncolytics Biotech News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapSucker Stock

Oncolytics rises as it schedules FDA talks on anal cancer drug

** Shares of biotech firm Oncolytics Biotech ONCY.O rise 2% to $0.97

** Co says it will meet the FDA on April 16 to discuss a possible approval path for its experimental anal cancer drug pelareorep

** This rare cancer starts in anal canal and few options exist once standard treatments fail

** Co says it plans to propose a single‑arm study combining pelareorep with a type of cancer immunotherapy in patients who have no approved alternatives

** Earlier study showed about a 30% tumor response rate lasting around 17 months, compared with 10%–14% and about 9.5 months for existing options, co says

** Including session's move, stock up ~12% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Recent news on Oncolytics Biotech

See all news